|
melanoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Besides, MEMD/ALCAM is also expressed in cultured endothelial cells, pericytes and melanocytes, in xenografts derived from the radial and vertical growth phase and in 4 of 13 melanoma metastasis lesions.
|
9502422 |
1998 |
|
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions.
|
12481253 |
2003 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The homophilic cell adhesion function of wild-type ALCAM mediates homotypic clustering of melanoma cells and would, thus, antagonize cell release from the primary tumor, an early prerequisite for metastasis.
|
15140234 |
2004 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data indicate that the intact cell adhesion function of ALCAM may both favor primary tumor growth and represent a rate-limiting step for tissue invasion from VGP melanoma.
|
15140234 |
2004 |
|
melanoma
|
0.080 |
Biomarker
|
disease |
LHGDN |
These data indicate that the intact cell adhesion function of ALCAM may both favor primary tumor growth and represent a rate-limiting step for tissue invasion from VGP melanoma.
|
15140234 |
2004 |
|
melanoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
These data indicate that the intact cell adhesion function of ALCAM may both favor primary tumor growth and represent a rate-limiting step for tissue invasion from VGP melanoma.
|
15140234 |
2004 |
|
Carcinoma
|
0.320 |
Biomarker
|
group |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Carcinoma
|
0.320 |
AlteredExpression
|
group |
BEFREE |
Immunohistologically detected over-expression of MEMD and CD24 was identified in 86% and 38.5% of prostate carcinomas respectively, and both were predictive of PSA relapse.
|
15532095 |
2005 |
|
Animal Mammary Neoplasms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Mammary Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Anaplastic carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Carcinoma, Spindle-Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Undifferentiated carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Carcinomatosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Mammary Carcinoma, Animal
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
MEMD/ALCAM overexpression in ESCCs was associated with late clinical stage (p = 0.002, OR = 3.619), enhanced tumor invasiveness (p = 0.002, OR = 3.619), and nodal metastasis (p = 0.000, OR = 4.206).
|
16024937 |
2005 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
LHGDN |
MEMD/ALCAM overexpression in ESCCs was associated with late clinical stage (p = 0.002, OR = 3.619), enhanced tumor invasiveness (p = 0.002, OR = 3.619), and nodal metastasis (p = 0.000, OR = 4.206).
|
16024937 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MEMD/ALCAM overexpression in ESCCs was associated with late clinical stage (p = 0.002, OR = 3.619), enhanced tumor invasiveness (p = 0.002, OR = 3.619), and nodal metastasis (p = 0.000, OR = 4.206).
|
16024937 |
2005 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD) could function as a cell surface sensor for cell density, controlling the transition between local cell proliferation and tissue invasion in melanoma progression.
|
16204050 |
2005 |
|
melanoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Surprisingly, truncation of ALCAM severely impaired MMP-2 activation in a nude mouse xenograft model, in which we previously observed diminished primary tumor growth and enhanced melanoma metastasis.
|
16204050 |
2005 |
|
Carcinogenesis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
The aim of this study was to determine the clinical significance of MEMD/ALCAM in esophageal tumorigenesis.
|
16024937 |
2005 |
|
Squamous cell carcinoma
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma.
|
16024937 |
2005 |
|
Esophageal Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
To our knowledge, this is the first report showing MEMD expression at pre-malignant stage (dysplasia), suggesting that MEMD/ALCAM expression is an early event in the development of esophageal cancer.
|
16024937 |
2005 |
|
Esophageal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To our knowledge, this is the first report showing MEMD expression at pre-malignant stage (dysplasia), suggesting that MEMD/ALCAM expression is an early event in the development of esophageal cancer.
|
16024937 |
2005 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MEMD/ALCAM overexpression in ESCCs was associated with late clinical stage (p = 0.002, OR = 3.619), enhanced tumor invasiveness (p = 0.002, OR = 3.619), and nodal metastasis (p = 0.000, OR = 4.206).
|
16024937 |
2005 |